Iohexol Imax (Iohexol)

Iohexol contains iodine atoms that strongly absorb X‑rays. When injected, it increases the radiodensity of the vascular and extracellular spaces, creating a temporary contrast between structures. This heightened contrast enables imaging equipment to differentiate organs, vessels, and tissues more distinctly.

The dose of Iohexol Imax is determined by the prescribing clinician based on the specific imaging study, patient weight, renal function, and the required level of contrast. Healthcare professionals calculate the appropriate volume and concentration for each individual case.

Iohexol Imax is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It should be used only when the diagnostic benefit outweighs potential risks. Breastfeeding mothers should consult their physician, as the drug may be excreted in milk.

To order Iohexol Imax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Iohexol Imax is a non‑ionic, low‑osmolality iodinated contrast agent, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image enhancement while reducing the incidence of discomfort and adverse renal effects, making it a preferred choice for many diagnostic procedures.

Iohexol Imax should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Do not freeze or shake the vial before use.

Iohexol Imax is administered intravenously or intra‑arterially by a qualified healthcare professional. The solution is injected as a bolus or infusion, depending on the imaging protocol, using aseptic technique and appropriate catheter or needle size.

The most serious risks include severe allergic reactions (anaphylaxis), acute kidney injury, and cardiovascular collapse. Patients with known iodine allergy, impaired renal function, or unstable cardiovascular status should be closely monitored, and emergency measures must be readily available.

Iohexol Imax should be avoided in patients with a documented hypersensitivity to iodinated contrast media, those with uncontrolled severe renal impairment, and individuals who have recently undergone radioactive iodine therapy. Clinicians must assess each patient’s medical history before administration.